These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21715084)

  • 1. SRD5A polymorphisms and biochemical failure after radical prostatectomy.
    Audet-Walsh E; Bellemare J; Nadeau G; Lacombe L; Fradet Y; Fradet V; Huang SP; Bao BY; Douville P; Girard H; Guillemette C; Lévesque E
    Eur Urol; 2011 Dec; 60(6):1226-34. PubMed ID: 21715084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variations in genes involved in testosterone metabolism are associated with prostate cancer progression: A Spanish multicenter study.
    Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Rodríguez-Melcón JI; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC
    Urol Oncol; 2015 Jul; 33(7):331.e1-7. PubMed ID: 25960412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.
    Huang SP; Lévesque E; Guillemette C; Yu CC; Huang CY; Lin VC; Chung IC; Chen LC; Laverdière I; Lacombe L; Fradet Y; Chang TY; Lee HZ; Juang SH; Bao BY
    Int J Cancer; 2014 Dec; 135(11):2661-7. PubMed ID: 24740842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY; Kim HJ; Cheong HS; Myung SC
    Korean J Urol; 2015 Jan; 56(1):19-30. PubMed ID: 25598933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.
    Gu C; Qu Y; Zhang G; Sun L; Zhu Y; Ye D
    Oncotarget; 2015 Oct; 6(31):32205-11. PubMed ID: 26320190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
    Audet-Walsh É; Bellemare J; Lacombe L; Fradet Y; Fradet V; Douville P; Guillemette C; Lévesque É
    Eur Urol; 2012 Jul; 62(1):88-96. PubMed ID: 22209174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
    Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
    Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
    Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men.
    Jiang J; Tang NL; Ohlsson C; Eriksson AL; Vandenput L; Liao C; Wang X; Chan FW; Kwok A; Orwoll E; Kwok TC; Woo J; Leung PC
    Clin Chem; 2010 Nov; 56(11):1742-9. PubMed ID: 20855474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
    Lévesque É; Huang SP; Audet-Walsh É; Lacombe L; Bao BY; Fradet Y; Laverdière I; Rouleau M; Huang CY; Yu CC; Caron P; Guillemette C
    Clin Cancer Res; 2013 Feb; 19(3):699-709. PubMed ID: 23186779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
    Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy.
    Laverdière I; Flageole C; Audet-Walsh É; Caron P; Fradet Y; Lacombe L; Lévesque É; Guillemette C
    Endocr Relat Cancer; 2015 Feb; 22(1):77-85. PubMed ID: 25452636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.